Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57,159,091
-
Total 13F shares
-
32,097,220
-
Share change
-
+1,363,514
-
Total reported value
-
$107,523,400
-
Put/Call ratio
-
1936%
-
Price per share
-
$3.35
-
Number of holders
-
92
-
Value change
-
+$4,413,894
-
Number of buys
-
48
-
Number of sells
-
37
Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q2 2024
As of 30 Jun 2024,
Design Therapeutics, Inc. - Common Stock (DSGN) was held by
92 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
32,097,220 shares.
The largest 10 holders included
SR One Capital Management, LP, Logos Global Management LP, BlackRock Inc., BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Almitas Capital LLC, Frazier Life Sciences Management, L.P., Point72 Asset Management, L.P., and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
92
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.